Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 76 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR ¿Las gammagrafías óseas muestran el cáncer? April 28, 2021 2025 ESMO Society Award recipients announced August 5, 2025 Επικοινωνία January 18, 2019 On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing... February 3, 2022 Load more HOT NEWS Study Links Non-Diet Soda Consumption with a Higher Risk of Death... Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... Our nurses answer your frequently asked questions about cancer
